Najoua Lassoued

Dr. Najoua Lassoued

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Endocrinology, Diabetes & Metabolism Case Reports
Verified
Journal Article
Open access
PDF file
NLNajoua Lassoued
Najoua Lassoued
WAWafa Alaya
Wafa Alaya
SRSenda Rebai
Senda Rebai
SASondos Arfa
Sondos Arfa
BZBaha Zantour
Baha Zantour
MSMohamed Habib Sfar
Mohamed Habib Sfar
Summary: Autoimmune polyglandular syndrome (APS) type 2 is characterized by the presence of Addison’s disease (AD) along with autoimmune thyroid disease and/or type 1 diabetes. APS type 2 is known as Schmidt’s syndrome when autoimmune adrenal insufficiency is associated with chronic lymphocytic thyroiditis. We report a very rare case of a 28-year-old female patient who had Schmidt’s syndrome revealed by a thyroid storm (TS) concomitant with an acute adrenal crisis. The onset of AD resulted in a surgical emergency. The patient presented with cardiogenic shock and an acute abdomen. The precipitation factor was Hashitoxicosis presented as TS. This life-threatening condition was successfully reversed with aggressive medical therapy based on antithyroid drugs and intravenous glucocorticoids. This hyperthyroid phase lasted for a period of 8 months. The patient eventually developed hypothyroidism, suggesting that Hashimoto's thyroiditis was the most likely diagnosis. She was started on levothyroxine replacement therapy and remained euthyroid on levothyroxine. The case we describe had several diagnostic pitfalls that are discussed both at the start as well as during the evolution. Learning points: Autoimmune diseases can appear concomitantly or succeed each other over time. The clinician must be vigilant to detect these diseases in time in order to avoid a misdiagnosis of a life-threatening emergency such as adrenal insufficiency or thyroid storm. Thyroid storm is an uncommon but life-threatening manifestation of hyperthyroidism. Diagnosis is dependent on clinical symptoms, and no specific laboratory tests are available. Glucocorticoids should be used in the treatment of thyroid storm because they have an inhibitory effect on peripheral conversion of T4 to T3. In patients who have severe thyrotoxicosis, especially in conjunction with hypotension, treatment with glucocorticoids has become standard practice because of the possibility of relative adrenal insufficiency or the possibility of undiagnosed Addison’s disease. The differential diagnosis of hyperthyroidism can be challenging. Graves’ disease can be discussed in view of the severity of the clinical presentation and the prolonged duration of the hyperthyroid phase. Hashitoxicosis is the initial hyperthyroid phase in chronic autoimmune thyroiditis. The hyperthyroid phase is always followed by definitive resolution, with persistent euthyroidism and no hyperthyroid relapses. Synthetic antithyroid drugs may be prescribed during the hyperthyroid phase of Hashimoto thyroiditis if the clinical presentation is severe and the duration of the hyperthyroid phase is prolonged.

30 May 2022 in Heliyon
Verified
Journal Article
Open access
NLNajoua Lassoued
Najoua Lassoued
BZBaha Zantour
Baha Zantour
WAWafa Alaya
Wafa Alaya
MSMohamed Hbib Sfar
Mohamed Hbib Sfar
The clinical requirements and the indication of the Synacthen test are increasing. The objective of our study is to determine a baseline cortisol level that reliably predicts the response to Synacthen test in a low-risk group of patients. We performed a cross-sectional analysis of all Synacthen tests conducted between January 2017 and June 2018. The diagnostic accuracy of basal cortisol levels as a predictor of an adequate response to Synacthen test was evaluated by ROC curve analysis. One hundred and fifty-three patients were included. A baseline cortisol level 147.5 ng/mL showed a specificity of 100% but a sensitivity of 1.2% for an adequate response to the Synacthen test. According to the ROC curve, the optimal baseline cortisol level for predicting an adequate response to the Synacthen test was 85 ng/mL with an AUC of 0.808 (95% CI [0.738–0.877]). We propose a basal cortisol level assay as a first step in the evaluation of patients with suspected adrenal insufficiency.

24 September 2021 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
STS. Trigui
S. Trigui
FBF. Boubaker
F. Boubaker
ABA. Belkacem
A. Belkacem
RAR. Ajili
R. Ajili
HMH.E.O. Mrabet
H.E.O. Mrabet
MSM.H. Sfar
M.H. Sfar

24 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MAMohamed Nour Bou Ali
Mohamed Nour Bou Ali
NLNajoua Lassoued
Najoua Lassoued
HMHoussem Mahmoud
Houssem Mahmoud
EMEmna Mnif
Emna Mnif
SHSlim Haouet
Slim Haouet
MHMehdi Hasnaoui
Mehdi Hasnaoui
Purpose: To evaluate a medical vision–language foundation model fine-tuned on thyroid ultrasound images, with or without the radiologist’s structured descriptors, against expert-rated EU-TIRADS for the classification of thyroid nodules as benign or malignant. Materials and Methods: This retrospective study included nodules that underwent ultrasound-guided fine-needle aspiration (FNA) between January 2019 and August 2025 in two Tunisian centers, with consecutive recruitment, together with a selection of images from an international public dataset. Of 1,580 nodules, 1,456 (272 malignant; 1,280 patients) with an interpretable cytological or histological reference standard were allocated at patient level to training (n = 942), validation (n = 258) and a test set sealed before training (n = 256; 51 malignant). MedGemma 1.5 4B was fine-tuned with low-rank adaptation under four input configurations: the image with nodule biometry, with or without age and sex (A, B); A with chain-of-thought supervision (C); and A plus the eleven qualitative descriptors of the radiologist’s structured report (D). The EU-TIRADS category was never a model input. Areas under the receiver operating characteristic curve (AUROCs) were compared with DeLong’s test and a prespecified non-inferiority margin of 0.05; EU-TIRADS ≥ 4 was the prespecified comparator, with ≥ 5 as a sensitivity analysis. Results: Config D reached an AUROC of 0.953 (95% CI 0.909–0.976), versus 0.948 (0.894–0.972) for EU-TIRADS (difference +0.004, 95% CI −0.016 to +0.025), which met the non-inferiority criterion; Configs A–C, without the qualitative descriptors, reached 0.883–0.892 (Holm-adjusted p = 0.045 versus EU-TIRADS). At ≥ 4, EU-TIRADS had a sensitivity of 98.0% and produced 94 false positives among 205 benign nodules; at a threshold fixed on validation data, Config D reclassified 72 of them as negative while missing two additional cancers. Against EU-TIRADS ≥ 5 (sensitivity 92.2%, specificity 95.1%), Config D at its native threshold (88.2%, 94.1%) did not classify more nodules correctly (McNemar p = 0.22), and at its two other thresholds it classified fewer nodules correctly (p = 0.004 and 0.007). Raw probabilities were miscalibrated (expected calibration error 0.117 for Config D), and Platt scaling within the test set reduced this error to 0.019–0.040. Conclusion: Given the ultrasound image together with the radiologist’s structured descriptors, the fine-tuned model matched expert EU-TIRADS discrimination and, against the ≥ 4 threshold, reclassified most false positives as negative, a gain concentrated in category 4 and based on only three cancers in category 4. It is best positioned as a report-standardizing second reader in the EU-TIRADS 4 gray zone, pending prospective external validation. Summary Statement: A fine-tuned medical vision–language model given the ultrasound image and the radiologist’s structured report matched expert EU-TIRADS discrimination of thyroid nodules and would have deferred most aspirations of benign category 4 nodules, at the cost of one or two missed category 4 cancers depending on the threshold, based on only three cancers in category 4. Key Points: On a test set of 256 thyroid nodules sealed before training, the model given the ultrasound image and the radiologist’s 16-field structured report reached an area under the receiver operating characteristic curve of 0.953, non-inferior to expert EU-TIRADS (0.948). Against EU-TIRADS 4 or higher, the model reclassified as negative 72 of the 94 false-positive nodules at a threshold fixed on validation data, at the cost of two additional missed cancers. Adding the radiologist’s qualitative descriptors to the image raised the area under the curve from 0.892 (Config A) to 0.953, and Platt scaling reduced the calibration error of the model from 0.117 to 0.019–0.040.

3 April 2017 in Endocrinology & Metabolism International Journal
Verified
Journal Article
Open access
PDF file
NLNajoua Lassoued
Najoua Lassoued
FLFaten HadjKacem Najoua Lassoued
Faten HadjKacem Najoua Lassoued
MCMohamed Abid Nadia Charfi
Mohamed Abid Nadia Charfi
We report the case of a 40-year-old male presenting with an unilateral exophtalmos due to a large tumoral mass invading the skull base. Magnetic resonance imaging (MRI) showed extension of a large tumour (8*6*6 cm) into the right orbit. Endocrine evaluation revealed elevated serum prolactin (PRL) levels (161 290 ng/mL, NR < 12.07) leading to the diagnosis of an invasive giant prolactinoma. Treatment with Bromocriptine resulted in rapid decrease of serum PRL (3 months after initiation of treatment), reduction of tumour size with improvement of the exophtalmos. With reference to this case, we review the features of invasive giant prolactinomas. We point out the use of Dopamine agonists in the treatment of prolactinomas with such atypical presentation.

24 September 2021 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
MMM. Masmoudi
M. Masmoudi
CZC. Zitouni
C. Zitouni
MHM. Hasnaoui
M. Hasnaoui
TAT. Ben Arfi
T. Ben Arfi
NLNajoua Lassoued
Najoua Lassoued
KMK. Mighri
K. Mighri